Bajaj Healthcare Rallies 11% on DRDO Nod to Manufacture Oral Covid Drug

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Views On News
  • Jul 8, 2021 - Bajaj Healthcare Rallies 11% on DRDO Nod to Manufacture Oral Covid Drug

Bajaj Healthcare Rallies 11% on DRDO Nod to Manufacture Oral Covid Drug

Jul 8, 2021

Shares of Bajaj Healthcare surged 11% in early trade today after the company received license from defence research and development organisation (DRDO) to manufacture and market '2-Deoxy-D-Glucose' (2-DG).

This drug is used as a treatment of Covid-19, which is given as an oral intake.

The 2-DG Covid-19 control and treatment drug has been developed by the DRDO laboratory's Institute of Nuclear Medicine and Allied Sciences (INMAS), in collaboration with the pharma major Dr Reddy's Laboratories.

It has already received emergency approval from the drugs controller general of India (DCGI) for use on Covid-19 patients in the country.

The drug comes in powder form and retails at Rs 990 per sachet.

2-DG helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence.

The drug works by selectively accumulating in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production.

--- Advertisement ---
[Alert] Sell These 3 Stocks Immediately

These 3 stocks are ticking time bombs in your portfolio.

It is very likely that you could be owning these 3 overvalued...

fundamentally weak... ready to crash stocks... in your portfolio today.

Because many stock brokers have painted rosy pictures of these stocks. But the reality is starkly different.

If the market crashes, then these stocks could wipe out your wealth.

You should get rid of these stocks as soon as possible.

We are going to reveal details of these 3 landmines at our upcoming special event at 5 pm on September 24.

You can click here to sign-up. It's free

It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe Covid-19 patients as an adjunct therapy to the existing standard of care.

Commenting on license received from DRDO for 2-Deoxy-D-Glucose, Anil Jain, Joint Managing Director, Bajaj Healthcare said,

  • We hope the availability of an effective treatment such as 2-DG will considerably ease the pressure and offer patients much needed and timely therapy option.

    Most patients ailing from moderate to severe symptoms can benefit from the use of Deoxy-D-Glucose.

Bajaj Healthcare seeks compulsory license for Covid-19 drug

On 28 June 2021, Drugmaker Bajaj Healthcare requested the Indian patent office to grant a compulsory license to make Baricitinib, an Eli Lilly drug which has shown promise in treating Covid-19.

Bajaj Healthcare, which makes Covid drugs like favipiravir and ivermectin, has sought permission to make both the active pharmaceutical ingredient (API) and the formulation of Baricitinib.

The company approached Eli Lilly on two occasions, to sign the voluntary license for manufacturing and supply of Covid-19 drug Baricitinib.

REVEALED: 3 "Super Smallcaps" You Didn't Know About

Company's board approves listing on NSE

On Monday, Bajaj Healthcare has informed to the exchange regarding listing of equity shares on National Stock Exchange (NSE).

The board of directors of the company has considered and approved the listing of 13.7 m equity shares of Rs 10/- each of the company on NSE.

Key financial highlights for the March 2021 quarter

The company reported 11.5% year on year (YoY) rise in consolidated net revenues for the January - March quarter at Rs 1.3 bn.

Net profits in the quarter four were up 69.4% at Rs 212.8 m on the back of higher sales and lower raw material costs which helped the growth in profits.

In terms of verticals, the bulk drugs vertical reported 13% higher sales at Rs 1.3 bn while the formulations verticals saw its revenues falling by 17% at Rs 49.4 m.

The earnings before interest, depreciation, and tax (EBIDTA) contribution was sharply higher for the bulk drugs business and flat for formulations despite the fall in sales in the formulations vertical.

Equitymaster's view on the pharma sector

We reached out to Tanushree Banerjee, Co-Head of Research at Equitymaster, and editor of the premium stock recommendation service StockSelect, for her view on the pharma sector.

Here's what she has to say...

  • The second Covid wave has given a new lease of life to pharma stocks. As the sector continues to invest in capacities for new drugs, the profitability will depend on the companies' ability to seek USFDA approval for the plants.

    Or their ability to tie up with MNC pharma for producing variants of their vaccine.

--- Advertisement ---
INSIDER SECRET: An Astonishingly Easy Way to Pile Up Potentially 40-60% Gains in Just 1 Year

India's most well-connected trader with over 35 years of experience just confessed...

"This Lucrative Market Segment Could Leapfrog Over Nifty in The Next 12-16 Months"

... thanks to a massive and irreversible mega-trend fueling its growth!

In fact, he and his partner have already identified 2 spectacular stocks from this segment... which are ready to rake in potentially 40-60% gains in just 1 year... and make you big, fat profits!

The best part of them all...

Their Details Are Packed in This Special Report (Discover How to Claim it for Free)

How the stock markets reacted to Bajaj Healthcare

Shares of Bajaj Healthcare opened the day at Rs 950 on the BSE.

Its share price closed at Rs 978.3 (up 7.4%) on the BSE.

At its current price, it is trading at a P/E of 16.2.

The share touched its 52-week high of Rs 1,009.8 and 52-week low of Rs 277 on 8 July 2021 and 8 July 2020, respectively.

Over the last 30 days, the Bajaj Healthcare share price is up 28.4%. Over the last one year, the company's share price is up 243.6%.

About Bajaj Healthcare

Bajaj Healthcare is a leading manufacturer of APIs, intermediates and formulations established in the year 1993.

It specialises in manufacturing of amino acids, intermediates, API, formulations, and nutraceuticals.

The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 units to intermediates and 1 unit for formulation.

These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities.

Bajaj Healthcare has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East, and South America.

For more details about the company, you can have a look at Bajaj Healthcare factsheet and quarterly results on our website.

You can also compare Bajaj Healthcare with its peers.

Bajaj Healthcare vs DR Reddys Lab

Bajaj Healthcare vs Cipla

Bajaj Healthcare vs Lupin

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Equitymaster requests your view! Post a comment on "Bajaj Healthcare Rallies 11% on DRDO Nod to Manufacture Oral Covid Drug". Click here!


More Views on News

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Apollo Hospitals' Shares Rally Over 5%, Hit Record-High on Strong Results (Views On News)

Aug 16, 2021

The company reported a 73% YoY increase in revenue driven by an uptick in the hospital and pharmacy business.

J B Chemicals & Pharma's Decent Performance Puts Stock in Focus (Views On News)

Aug 13, 2021

The company seeks to expand the market for prescription lozenges with new launches this year.

Cipla Shares Tank Despite Strong Earnings (Views On News)

Aug 6, 2021

The stock fell 3.5% even as the company reported numbers higher than analysts' expectations.

Glenmark Life Sciences Makes Lacklustre Debut. Shares List At 4% Premium (Views On News)

Aug 6, 2021

Glenmark Life Sciences' IPO had received strong response from investors as the offer was subscribed 44.17 times.

More Views on News

Most Popular

All You Need to Know About Primary and Secondary Markets

A look at the various types of primary and secondary markets and the key differences between them.

5 Small-cap Stocks with Zero Debt (Views On News)

Sep 3, 2021

In this article, you will get a list of 5 debt free small-cap companies that are worth tracking.

Sansera Engineering IPO: Key Points to Consider (Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore (Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

Put the Odds in Your Favour to Find Smallcap Multibaggers (Profit Hunter)

Sep 3, 2021

A handy checklist to find multibagger smallcaps.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Sep 16, 2021 (Close)


  • Track your investment in BAJAJ HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks